Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 294-305
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.294
Table 4 Reported interventions based on patient problems
Primary concern | Sample | Conservative therapy | Operative therapy |
Lack of benefit | 325 | Stimulation adjusted: 160 Medication: 3 System check: 7 | Explant: 22 Replacement: 17 Pocket revision: 3 |
Pain or discomfort | 97 | Stimulation adjusted: 34 Medication: 4 System check: 2 | Explant: 8 Replacement: 1 Pocket revision: 7 |
Lead problem | 70 | Stimulation adjusted: 3 System check: 2 | Explant: 1 Replacement: 36 |
Programming problems | 30 | Stimulation adjusted: 11 | Replacement: 1 |
- Citation: Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
- URL: https://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i2.294